Start: June 1, 2021
End: January 1, 2023
This Phase 1 study will examine the safety and effects of TB006, a potential treatment for Alzheimer's disease in healthy adults, including individuals of Chinese descent. Participants will be randomly assigned to receive one dose of five possible concentrations (70 mg - 5000 mg) of TB006 or a placebo by IV infusion over one hour. Researchers will monitor participants for side effects for 75 days and also collect blood and spinal fluid samples at regular intervals to measure the levels of the drug in the body and immune system response.
Minimum Age: 18 Years
Maximum Age: 55 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Collaborative Neuroscience Research, LLC (CNS)
Long Beach, CA 90806
Lead: TrueBinding, Inc.
Source: ClinicalTrials.gov ID: NCT04920786